Efgartigimod, an FcRn antagonist initially developed to treat autoimmune conditions such as myasthenia gravis and immune thrombocytopenic purpura, has shown promising efficacy in preclinical models of metabolic diseases (5, 23, 123). Here, FCGRT is linked to Other metabolic disease.